Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
labetalol + glyceryl trinitrate
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Sublingual
01
Overview
A combination of labetalol, an alpha and beta adrenergic antagonist, and glyceryl trinitrate, a vasodilator. Labetalol blocks beta-1 receptors in the heart and alpha-1 receptors in blood vessels, while glyceryl trinitrate works by relaxing blood vessels. This combination is used primarily for managing hypertension and angina, though requires careful monitoring as it may cause excessive blood pressure reduction.
- Other names
- labetalol + nitroglycerin
02
Targets
ADRA1A (α1A)ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on labetalol + glyceryl trinitrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on labetalol + glyceryl trinitrate.